...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Iranian journal of psychiatry. >Amantadine as Augmentation in Managing Opioid Withdrawal with Clonidine: a randomized controlled trial
【24h】

Amantadine as Augmentation in Managing Opioid Withdrawal with Clonidine: a randomized controlled trial

机译：金刚烷胺作为可乐定阿片类药物治疗的增强剂：一项随机对照试验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

ObjectiveWithdrawal symptoms are a main reason of continuous use of opioid. This study compares the efficacy of augmentation of amantadine with clonidine in decreasing opioid withdrawal symptoms.MethodsThis double-blind randomized clinical trial was carried out in the detoxification and rehabilitation inpatient ward at Razi Hospital, Tabriz, Iran during 2012. The patients were randomly assigned to receive clonidine or clonidine plus amantadine; and withdrawal symptoms were evaluated in the admission day and 24, 48, and 72 hours later. Data were analyzed using SPSS by the 2*2 repeated analyses of variances (ANOVA).ResultsFrom the total of 69 participants, 30 patients completed the trial in each group. The severity of symptoms, however, had an increasing trend in both groups. Analysis of variance of the symptom severity score (by The Clinical Opiate Withdrawal Scale) revealed a significant group-time interaction, and the patients who were receiving amantadine experienced milder symptoms.ConclusionsTreatment of opioid withdrawal symptoms with amantadine and clonidine would result in a better outcome compared with clonidine alone.
机译：目的戒断症状是持续使用阿片类药物的主要原因。本研究比较了金刚烷胺与可乐定增强药物在减轻阿片类药物戒断症状中的功效。方法该双盲随机临床试验于2012年在伊朗大不里士Razi医院的排毒和康复住院病房进行。接受可乐定或可乐定加金刚烷胺;在入院当天，24、48和72小时后评估了戒断症状。使用SPSS通过2 * 2重复方差分析（ANOVA）分析数据。结果在总共69名参与者中，每组30名患者完成了该试验。但是，两组的症状严重程度都有增加的趋势。症状严重程度评分方差分析（通过临床阿片戒断量表）显示出显着的组间交互作用，接受金刚烷胺治疗的患者出现较轻的症状。结论金刚烷胺和可乐定治疗阿片类戒断症状会导致更好的结果与单独的可乐定相比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号